Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

• Váldodahkkit: Xiaomin Wan (Dahkki), Xiaohui Zeng (Dahkki), Liubao Peng (Dahkki), Ye Peng (Dahkki), Qiao Liu (Dahkki), Lidan Yi (Dahkki), Xia Luo (Dahkki), Qijian Deng (Dahkki), Chongqing Tan (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2021-08-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Objective: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab vs. chemotherapy in the first-line setting for patients with advanced non-small-cell lung cancer (NSCLC) from the US payer perspective.Materials and methods: A Markov model wasdeveloped to evaluate the cost and effec...